Determine the necessary mass, volume, or concentration for preparing a solution.
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
SKU | Size | Availability | Price | Qty |
---|---|---|---|---|
M648007-5mg | 5mg | Available within 8-12 weeks(?) Production requires sourcing of materials. We appreciate your patience and understanding. | $450.90 | |
M648007-10mg | 10mg | Available within 8-12 weeks(?) Production requires sourcing of materials. We appreciate your patience and understanding. | $750.90 | |
M648007-50mg | 50mg | Available within 8-12 weeks(?) Production requires sourcing of materials. We appreciate your patience and understanding. | $2,250.90 | |
M648007-100mg | 100mg | Available within 8-12 weeks(?) Production requires sourcing of materials. We appreciate your patience and understanding. | $3,350.90 |
Synonyms | MK-0429|227963-15-7|MK-429|CHEMBL145085|1JL033A2D0|(3S)-3-(6-Methoxy-3-pyridyl)-3-(2-oxo-3-(3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)propyl)imidazolidin-1-yl)propanoic acid|J1.969.455K|(S)-3-(6-methoxypyridin-3-yl)-3-(2-oxo-3-(3-(5,6,7,8-tetrahydro-1,8 |
---|---|
Specifications & Purity | ≥99% |
Biochemical and Physiological Mechanisms | MK-0429 (L-000845704) is an orally active, potent, selective and nonpeptide pan-integrin antagonist with IC 50 values of 1.6 nM, 2.8 nM, 0.1 nM, 0.7 nM, 0.5 nM and 12.2 nM for αvβ1 , αvβ3 , αvβ5 , αvβ6 , αvβ8 and α5β1 , respectively. |
Storage Temp | Store at -20°C |
Shipped In | Ice chest + Ice pads |
Product Description | MK-0429 (L-000845704) is an orally active, potent, selective and nonpeptide pan-integrin antagonist with IC 50 values of 1.6 nM, 2.8 nM, 0.1 nM, 0.7 nM, 0.5 nM and 12.2 nM for αvβ1 , αvβ3 , αvβ5 , αvβ6 , αvβ8 and α5β1 , respectively . In Vivo MK-0429 (100 or 300 mg/kg, p.o., twice daily b.i.d., 2 weeks) reduces metastatic tumor colony formation and area in the lungs. MK-0429 is safe and efficacious in significantly decreasing melanoma metastasis in the lungs . MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: B6D2F1 hybrid female miceDosage: 100 or 300 mg/kg Administration: P.o., twice daily (b.i.d.), 2 weeks Result: MK-0429 at 100 and 300 mg/kg reduced the number of metastatic tumor colonies by 64 and 57%, respectively, and the high dose also reduced the tumor area by 60% as compared to the vehicle. Form:Solid |
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
IUPAC Name | (3S)-3-(6-methoxypyridin-3-yl)-3-[2-oxo-3-[3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)propyl]imidazolidin-1-yl]propanoic acid |
---|---|
INCHI | InChI=1S/C23H29N5O4/c1-32-20-9-7-17(15-25-20)19(14-21(29)30)28-13-12-27(23(28)31)11-3-5-18-8-6-16-4-2-10-24-22(16)26-18/h6-9,15,19H,2-5,10-14H2,1H3,(H,24,26)(H,29,30)/t19-/m0/s1 |
InChi Key | HGFOOLONGOBCMP-IBGZPJMESA-N |
Canonical SMILES | COC1=NC=C(C=C1)C(CC(=O)O)N2CCN(C2=O)CCCC3=NC4=C(CCCN4)C=C3 |
Isomeric SMILES | COC1=NC=C(C=C1)[C@H](CC(=O)O)N2CCN(C2=O)CCCC3=NC4=C(CCCN4)C=C3 |
Alternate CAS | 227963-15-7 |
PubChem CID | 9853559 |
MeSH Entry Terms | 3-(6-methoxypyridin-3-yl)-3-(2-oxo-3-(3-(5,6,7,8-tetrahydro(1,8)naphthyridin-2-yl)propyl)imidazolidin-1-yl)propionic acid;3-(6-methoxypyridin-3-yl)-3-(2-oxo-3-(3-(5,6,7,8-tetrahydro-(1,8)naphthyridin-2-yl)propyl)imidazolidin-1-yl)propionic acid;L-00084570 |
Molecular Weight | 439.51 |
Enter Lot Number to search for COA:
Solubility | DMSO : 100 mg/mL (227.53 mM; Need ultrasonic) H2O : 2.78 mg/mL (6.33 mM; Need ultrasonic) |
---|